

B2
Cmcd. ¹⁰³ ~~152~~ (new) The formulation of Claim ¹⁰² ~~151~~, wherein
the concentration of benzyl alcohol is 10 mg/mL.

NOTE: Applicants attach at the end of this Preliminary Amendment a sheet containing the new Claims 141-152 for the Examiner's convenience.

Remarks

Amendments in the Specification. The amended title reflects the subject matter encompassed by the new claims. The amended cross-reference paragraph provides an updated listing of related U.S. application data. These amendments do not add new matter.

Amendments in the Claims. Applicants cancel all claims, namely, Claims 92-140, and submit new Claims 141-152. Applicants respectfully request that the new claims be entered.

Applicants reserve the right to file subsequent applications containing one or more of the claims that are hereby canceled.

The new claims are supported throughout the specification of the application as filed. Basis for each new claim is found at least at the place(s) described in the table below.

Claim	Basis
141	Claim 92; Examples 6-7; page 31 line 13 to page 32 line 5.
142	Examples 1-2; page 14, lines 22 to page 15, line 7; page 25 line 1 to page 28, line 4.
143	Page 35, lines 1-10.
144	Page 35, lines 1-10.
145, 147, 149, 151	Page 35, line 31 to page 36, line 9.
146, 148, 150, 152	Examples 6-7 and page 65, line 20 to page 66, line 15.

In summary, Applicants amend the title, the reference to related applications, cancel Claims 92-140, and add new Claims 141-152. The amendments add no new matter and are supported throughout the application.

Respectfully submitted,

James J. Kelley

Eli Lilly and Company
Patent Division/JAH
Lilly Corporate Center
Indianapolis, Indiana 46285

James J. Kelley
Attorney for Applicants
Registration No. 41,888
Phone: 317-277-8110

9 August 2001

New Claims 141-152 added by Preliminary Amendment

141. A pharmaceutically acceptable formulation comprising human FSH and benzyl alcohol in an aqueous diluent.

142. The formulation of Claim 141, wherein the human FSH is produced through the use of recombinant DNA technology.

143. The formulation of Claim 142, wherein the human FSH is at a concentration of about 5.0 $\mu\text{g/mL}$ to about 200 $\mu\text{g/mL}$.

144. The formulation of Claim 143, wherein the human FSH is at a concentration of 50 $\mu\text{g/mL}$ to about 200 $\mu\text{g/mL}$.

145. The formulation of Claim 144, further comprising sodium phosphate.

146. The formulation of Claim 145, wherein the concentration of benzyl alcohol is 10 mg/mL.

147. The formulation of Claim 143, further comprising sodium phosphate.

148. The formulation of Claim 147, wherein the concentration of benzyl alcohol is 10 mg/mL.

149. The formulation of Claim 142, further comprising sodium phosphate.

150. The formulation of Claim 149, wherein the concentration of benzyl alcohol is 10 mg/mL.

151. The formulation of Claim 141, further comprising sodium phosphate.

09528198 "081001

Hoffmann, James A. Lu, Jirong
FSH FORMULATION
Docket X-12383N

152. The formulation of Claim 151, wherein the concentration of benzyl alcohol is 10 mg/mL.

0928198 081001